KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Other Non-Current Assets for 11 consecutive years, with $59.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 8.96% year-over-year to $59.5 million, compared with a TTM value of $59.5 million through Dec 2025, down 8.96%, and an annual FY2025 reading of $59.5 million, down 8.96% over the prior year.
  • Other Non-Current Assets was $59.5 million for Q4 2025 at Alnylam Pharmaceuticals, down from $65.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $75.2 million in Q3 2023 and bottomed at $2.2 million in Q1 2023.
  • Average Other Non-Current Assets over 5 years is $39.6 million, with a median of $59.5 million recorded in 2025.
  • The sharpest move saw Other Non-Current Assets surged 3205.38% in 2024, then fell 8.96% in 2025.
  • Year by year, Other Non-Current Assets stood at $60.2 million in 2021, then increased by 9.78% to $66.1 million in 2022, then dropped by 6.34% to $61.9 million in 2023, then increased by 5.51% to $65.3 million in 2024, then decreased by 8.96% to $59.5 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ALNY at $59.5 million in Q4 2025, $65.3 million in Q4 2024, and $71.9 million in Q2 2024.